Want to see SE:BIOVIC.B full AI Analyst Report?
Top Page
Biovica International AB Class B
(BIOVIC.B)
Select Model
Select Model
Rating:53Neutral
Price Target:
kr0.43
▲(22.00% Upside)
Action:Reiterated
Date:07/25/26
The score is held back primarily by weak financial performance: large ongoing losses and continued cash burn outweigh strong revenue growth, despite a relatively low-leverage balance sheet. Technicals are supportive with price above key moving averages and positive MACD, but momentum looks near overbought. Valuation is penalized by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Revenue Growth
Accelerating revenue growth indicates improving commercial traction for Biovica’s diagnostics business. Continued top-line expansion can broaden the installed customer base and create operating leverage over time, provided the company can control costs and convert growth into sustainable margins.
Negative Factors
Persistent Net Losses
Large and persistent losses show that revenue growth has not yet translated into a viable earnings model. Until operating costs are brought below revenue, Biovica’s ability to self-fund expansion remains constrained and future profitability depends on a substantial improvement in execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Accelerating revenue growth indicates improving commercial traction for Biovica’s diagnostics business. Continued top-line expansion can broaden the installed customer base and create operating leverage over time, provided the company can control costs and convert growth into sustainable margins.
Read all positive factors
Biovica International AB Class B (BIOVIC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr121.58M
Dividend YieldN/A
Average Volume (3M)525.09K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth55.24%
EPS Growth70.00%
CountrySE
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.36
Shares Outstanding277,487,200
10 Day Avg. Volume571,125
30 Day Avg. Volume525,089
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.95
Price to Sales (P/S)6.14
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr25.70M
Biovica International AB Class B Business Overview & Revenue Model
Company Description
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of...
How the Company Makes Money
Biovica makes money primarily by selling access to and usage of its DiviTum blood test and related services. Key revenue streams include: (1) sales associated with testing (e.g., provision of the DiviTum assay for use in laboratories and/or fees t...
Biovica International AB Class B Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.38M | 8.62M | 7.29M | 3.38M | 2.04M |
| Gross Profit | -70.05M | 8.08M | 6.88M | 4.62M | 4.67M |
| EBITDA | -61.75M | -76.22M | -119.51M | -105.96M | -53.47M |
| Net Income | -69.86M | -87.62M | -124.82M | -110.49M | -60.00M |
Balance Sheet | |||||
| Total Assets | 107.75M | 64.95M | 131.41M | 172.29M | 151.63M |
| Cash, Cash Equivalents and Short-Term Investments | 70.41M | 24.41M | 79.41M | 114.33M | 89.79M |
| Total Debt | 4.30M | 4.65M | 7.83M | 10.45M | 13.25M |
| Total Liabilities | 21.42M | 21.74M | 34.77M | 33.65M | 27.54M |
| Stockholders Equity | 86.33M | 43.21M | 96.64M | 138.63M | 124.09M |
Cash Flow | |||||
| Free Cash Flow | -63.28M | -85.65M | -114.72M | -97.42M | -55.52M |
| Operating Cash Flow | -62.81M | -85.37M | -114.58M | -94.64M | -52.13M |
| Investing Cash Flow | -474.00K | -287.00K | -585.00K | -2.78M | -3.40M |
| Financing Cash Flow | 109.36M | 30.93M | 79.50M | 122.01M | -136.00K |
Biovica International AB Class B Technical Analysis
Negative
0.35
Price Trends
0.46
Negative
0.40
Positive
0.41
Positive
Market Momentum
-0.01
Positive
37.10
Neutral
35.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.46, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 35.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOVIC.B.
Biovica International AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr497.63M | 2.60 | 63.09% | ― | ― | ― | |
73 Outperform | kr342.93M | 4.51 | 94.09% | ― | 135.48% | ― | |
56 Neutral | kr43.00M | 15.32 | 21.37% | ― | 837.37% | ― | |
53 Neutral | kr121.58M | -1.17 | -81.76% | ― | 55.24% | 70.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr91.02M | -2.42 | -106.23% | ― | -97.37% | 25.28% |
* Healthcare Sector Average
SE:BIOVIC.B
Biovica International AB Class B
0.42
-0.21
-32.96%
SE:ELIC
Elicera Therapeutics AB
2.83
-3.83
-57.53%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.06
-37.14%
SE:CANTA
Cantargia AB
1.73
-0.86
-33.20%
SE:SPRINT
Sprint Bioscience AB
3.24
2.63
431.15%
SE:FLUI
Fluicell AB
30.40
16.80
123.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.